It is clear that LAR-TNBC has a poor pathological complete response (pCR) [11]; and anti-androgen therapy (to kill the slow-growing cells) combined with standard chemotherapy drugs, such as paclitaxel (to kill rapidly dividing tumor cells), showed promising results in AR+-TNBC preclinical models [12,14]. Here, AR is linked to neoplasm.